Incidence and predictors of excessive warfarin anticoagulation in patients with atrial fibrillation—The EWA study

Samuli Jaakkola¹, Ilpo Nuotio¹,², Tuomas O. Kiviniemi¹, Raine Virtanen¹,³, Melina Issakoff⁴, K. E. Juhani Airaksinen¹*

¹ Heart Center, Turku University Hospital and University of Turku, Turku, Finland, ² Department of Acute Internal Medicine, Turku University Hospital and University of Turku, Turku, Finland, ³ Department of Cardiology, Turku City Hospital, Turku, Finland, ⁴ University of Turku, Turku, Finland

* juhani.airaksinen@tyks.fi

Abstract

Vitamin K antagonist warfarin is widely used in clinical practice and excessive anticoagulation is a well-known complication of this therapy. Little is known about permanent and temporary predictors for severe overanticoagulation. The aim of this study was to investigate the occurrence and predicting factors for episodes with very high (≥9) international normalized ratio (INR) values in warfarin treated patients with atrial fibrillation (AF). Excessive Warfarin Anticoagulation (EWA) study screened all patients (n = 13618) in the Turku University Hospital region with an INR ≥2 between years 2003–2015. Patients using warfarin anticoagulation for AF with very high (≥9) INR values (EWA Group) were identified (n = 412 patients) and their characteristics were compared to a control group (n = 405) of AF patients with stable INR during long-term follow-up. Over 20% (n = 92) of the EWA patients had more than one event of very high INR and in 105 (25.5%) patients EWA led to a bleeding event. Of the several temporary and permanent EWA risk factors observed, strongest were excessive alcohol consumption in 9.6% of patients (OR 24.4, 95% CI 9.9–50.4, p < 0.0001) and reduced renal function (OR 15.2, 95% CI 5.67–40.7, p < 0.0001). Recent antibiotic or antifungal medication, recent hospitalization or outpatient clinic visit and the first 6 months of warfarin use were the most significant temporary risk factors for EWA. Excessive warfarin anticoagulation can be predicted with several permanent and temporary clinical risk factors, many of which are modifiable.

Introduction

Excessive anticoagulation and hemorrhage are well known complications of vitamin K antagonist (VKA) warfarin therapy. High international normalized ratio (INR) level predisposes to significant bleeds and independently increases morbidity and mortality also through mechanisms other than bleeding [1–6]. Although overanticoagulation related mortality can be partly explained with spontaneous INR elevations in critically ill patients, high INR values due to
inappropriate warfarin dose adjustments have been reported to increase the risk even more [7]. These findings emphasize the importance of identifying risk factors for high INR values. Since there are no large-scale studies on very high INR values in VKA patients, we sought to evaluate the incidence, patient characteristics and predictors of excessive anticoagulation in patients with atrial fibrillation (AF) on warfarin treatment in a large well-defined patient population.

Methods

The Excessive Warfarin Anticoagulation (EWA) study (ClinicalTrials.gov Identifier: NCT02761941) is part of a series of research projects addressing anticoagulation and complications related to AF [8, 9]. In this study, we screened with computer searches all INR results between the years 2003 and 2015 from the laboratory database provided by Turku University Hospital laboratory service (TYKSLAB). A total of 13618 patients living in the Turku University Hospital catchment area with at least one INR value of ≥2 were identified. Of the 961431 INR test results in this patient group, 75.0% were ≥2. Excessive warfarin anticoagulation was defined as INR value ≥9 (which is the upper numerical measurement range of the laboratory) at any time during the study period. Consequently, we could identify 412 patients (age ≥18 years) with a prior diagnosis of AF, warfarin anticoagulation and at least one occasion with a very high INR (≥9) value. In patients with multiple events with INR values ≥9, only the first event was included in the present analysis.

To further evaluate baseline characteristics and temporary clinical factors predisposing to excessive anticoagulation a control group of 405 patients with stable anticoagulation was identified from the same database by selecting patients with a diagnosis of AF on long-term (>730 days) warfarin anticoagulation with no high INR (>4) values in regular controls (individual mean interval of INR tests 32 days, maximum interval 60 days). The date with the highest INR value (between 2.7–4.0) was selected as the index date for the data collection. All patients filling these criteria were included in the Control group.

Comprehensive laboratory data were collected through computer searches from the laboratory database. All individual patient records from Turku University Hospital and Turku City Hospital were reviewed using a standardized electronic case report form to collect information on patient characteristics, medication, preceding events, indication for warfarin treatment, clinical manifestation and patient management during the high INR event.

The study protocol was approved by the Medical Ethics Committee of the Hospital District of Southwest Finland. Informed consent was not required, because of the register-based nature of the study. The study complies with the Declaration of Helsinki.

Definitions

Psychiatric disorder included a diagnosis of depression, bipolar disorder or schizophrenia. Dementia was defined as a diagnosis of Alzheimer’s disease, vascular dementia, Lewy body dementia or mixed dementia regardless of the disease stage. Alcohol abuse consisted of an alcohol related diagnosis or a hospital/health care center visit due to alcohol use. Independent living was defined as living at home independently without outside help in daily routines. Recent antibiotic therapy included any antibiotic drug during the preceding 14 days of the index event date. Liver disease was defined as cirrhosis, hepatitis, cholangitis, metastatic liver nodules, unspecific liver failure, tumor in the liver or fatty liver disease. Estimated glomerular filtration rate (eGFR) was calculated using CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation to classify renal function according to KDIGO (Kidney Disease Improving Global Outcomes) clinical practice guidelines [10].
Statistical analysis

Continuous variables were reported as mean ± standard deviation if they were normally distributed. Categorical variables were described with absolute and relative (percentage) frequencies. Comparisons between study subgroups were performed with Mann-Whitney U test. Chi-square test and Fisher’s exact test were used for categorical variables. For all variables with more than 0.5% missing data, the exact number of patients with missing data is marked in the table. A binary stepwise logistic regression analysis (backward Wald) was performed to identify independent predictors of very high INR values. Predictors with p < 0.05 in the univariate analysis were included in the multivariate analysis. All tests were two-sided and statistical significance was set at 5%. This manuscript was written following STROBE guidelines for the reporting of observational studies [11]. Statistical analyses were performed with SPSS software (version 23.0, SPSS, Inc., Chicago, Illinois) and SAS software (version 9.4, SAS Institute, Inc., Cary, North Carolina).

Results

We identified 564 patients (4.1% of patients with INR ≥2) with very high INR (≥9) values comprising 0.08% of all INR measurements and 0.10% of INR measurements ≥ 2.0. A total of 412 patients (EWA Group) living in the Turku University Hospital catchment area had AF and at least one very high (≥9) INR value. There were 92 patients (22.3%) in the EWA group with multiple (2 to 5) episodes with INR ≥9. Over half (52.7%) of the patients in the EWA Group had at least one INR value of 5–9 before the index event and 19.7% of the patients in the preceding year.

Only 105 (25.5%) patients had a significant bleeding related to the very high INR. The baseline characteristics of the patients in the EWA Group and controls with stable warfarin anticoagulation are presented in Table 1. Logistic regression analyses identified several strong independent predictors of very high INR value (Table 2). The number of patients with EWA in different (permanent, temporary or lifestyle related) risk factor categories is illustrated in Fig 1.

Permanent risk factors

A chronic medical condition predicting the risk of severe overanticoagulation (heart failure, active cancer, severe renal dysfunction and mechanical heart valve prosthesis) was present in 236 patients (57.3%) in the EWA group and in 72 (17.8%) control patients with stable anticoagulation. Only 11.5% of patients (n = 94) had normal eGFR (>90) and almost half (45.4%, n = 371) of the patients had mildly to moderately decreased renal function (eGFR 60–30). Impaired renal function was a significant predictor of EWA, with an odds ratio of over 15 in patients with eGFR < 30. EWA was observed in all patients with eGFR < 30. EWA was observed in all patients with eGFR < 15.

Temporary predisposing factors

A temporary risk factor was found in 204 patients (49.5%) with EWA and 76 control patients (18.8%). Antibiotic or antifungal treatment preceded EWA in 28.6% of patients and caused a 4.6-fold risk for severe overanticoagulation compared to patients with stable INR. An outpatient visit to emergency clinic or health center or short hospitalization for a treatment of a medical condition was observed in 37.6% (n = 155) in the preceding 30 days before EWA causing a 2.4-fold increase in the risk of very high INR event compared to patients without EWA. Patients on chemotherapeutic agents had a 5.6-fold risk of overanticoagulation. EWA occurred during the first 6 months of warfarin treatment in 21.2% of patients in the EWA group. The
Table 1. Patient Characteristics.

| Patient characteristic                | EWA Group (n = 412) | Control Group (n = 405) | P-value  |
|---------------------------------------|---------------------|-------------------------|----------|
| Age (years)                           | 77.7±10.5           | 76.6±8.5                | 0.05     |
| Female                                | 217 (52.7)          | 223 (55.1)              | 0.493    |
| CHA\textsuperscript{2}DS\textsuperscript{2}-VASc | 4.0 ±1.8           | 3.7 ±1.5                | 0.0007   |
| Chronic heart failure                 | 155 (37.6)          | 55 (13.6)               | <0.0001  |
| Treatment for hypertension            | 235 (57.0)          | 283 (70.0)              | <0.0001  |
| Diabetes                              | 111 (26.9)          | 99 (24.4)               | 0.414    |
| History of ischemic stroke            | 82 (19.9)           | 57 (14.1)               | 0.027    |
| Coronary artery disease               | 130 (31.6)          | 89 (22.0)               | 0.002    |
| History of AMI                        | 80 (19.4)           | 41 (10.1)               | 0.0002   |
| Peripheral artery disease             | 34 (8.3)            | 9 (2.2)                 | <0.0001  |
| eGFR\textsuperscript{a}              |                    |                         |          |
| <15                                   | 28 (6.9)            | 0 (0.0)                 | <0.0001  |
| 15–30                                 | 58 (14.2)           | 5 (1.3)                 | <0.0001  |
| 30–60                                 | 148 (36.3)          | 132 (34.6)              | 0.614    |
| 60–90                                 | 114 (27.9)          | 211 (55.2)              | <0.0001  |
| >90                                   | 60 (14.7)           | 34 (8.9)                | 0.012    |
| Independent living\textsuperscript{b} | 248 (60.2)         | 338 (83.7)              | <0.0001  |
| Psychiatric disorder                  | 21 (5.1)            | 11 (2.7)                | 0.103    |
| Dementia                              | 57 (13.8)           | 23 (5.7)                | <0.0001  |
| History of malignancy                 | 104 (25.2)          | 53 (13.1)               | <0.0001  |
| Active malignancy                     | 48 (11.7)           | 15 (3.7)                | <0.0001  |
| Liver disease                         | 12 (2.9)            | 1 (0.2)                 | 0.003    |
| Mechanical heart valve                | 16 (3.9)            | 1 (0.3)                 | 0.0002   |
| Active smoker                         | 35 (8.5)            | 7 (1.7)                 | <0.0001  |
| Alcohol abuse\textsuperscript{c}      | 73 (17.7)           | 6 (1.5)                 | <0.0001  |
| Recent bleed\textsuperscript{d}       | 15 (3.6)            | 4 (1.0)                 | 0.018    |
| Recent surgical operation\textsuperscript{e} | 30 (7.3)         | 14 (3.5)                | 0.016    |
| Recent medical treatment\textsuperscript{f} | 155 (37.6)     | 67 (16.5)               | <0.0001  |
| Concomitant medication                |                     |                         |          |
| Cholesterol-lowering drugs            | 81 (19.7)           | 161 (39.8)              | <0.0001  |
| NSAID                                 | 11 (2.7)            | 3 (0.7)                 | 0.055    |
| Aspirin                               | 18 (4.4)            | 9 (2.2)                 | 0.116    |
| SSRI/SNRI                             | 38 (9.2)            | 11 (2.7)                | <0.0001  |
| Tramadol                              | 16 (3.9)            | 4 (1.0)                 | 0.011    |
| Dronedarone                           | 3 (0.7)             | 3 (0.7)                 | 1.000    |
| Amiodarone                            | 8 (1.9)             | 2 (0.5)                 | 0.107    |
| Paracetamole                          | 170 (41.3)          | 146 (36.0)              | 0.109    |
| Carbamazepine                         | 5 (1.2)             | 2 (0.5)                 | 0.451    |
| Antifungal medication                 | 17 (4.1)            | 0 (0.0)                 | <0.0001  |
| Recent antibiotic therapy\textsuperscript{g} | 107 (26.0)   | 22 (5.4)                | <0.0001  |
| Chemotherapeutic agents               | 12 (2.9)            | 3 (0.7)                 | 0.034    |

Values are mean ± SD, n (%)
AMI = acute myocardial infarction; CHA\textsuperscript{2}DS\textsuperscript{2}-VASc = Congestive heart failure, Hypertension, Age 75 (doubled), Diabetes mellitus, prior Stroke, transient ischemic attack or thromboembolism (doubled), Vascular disease, Age 65 to 74, Sex category (female); eGFR = estimated glomerular filtration rate (ml/min/1.73 m\textsuperscript{2}); NSAID = non steroidal anti-inflammatory drug; SSRI/SNRI = selective serotonin/norepinephrine reuptake inhibitor
\textsuperscript{a}Data missing on 27 patients (3.3%)
\textsuperscript{b}Living at home independently without outside help in daily routines
\textsuperscript{c}Alcohol related diagnosis or a hospital/health care center visit due to alcohol use
\textsuperscript{d}Bleeding event in the preceding 1 month
\textsuperscript{e}Operation in the preceding 1 month
\textsuperscript{f}Hospitalization or outpatient visit in the preceding 1 month
\textsuperscript{g}Antibiotic therapy in the preceding 14 days

https://doi.org/10.1371/journal.pone.0175975.t001
number of patients with EWA per 6 months of warfarin treatment after the initiation of warfarin is presented in Fig 2.

Use of carbamazepine, amiodarone, dronedarone or tramadol was recorded in only 28 (6.8%) patients in the EWA group and 11 (2.7%) in the control group. Individually they had no independent predictive value in the multivariate analysis. SSRI/SNRI use was of borderline significance in predicting EWA. There was no statistical difference between groups in the use of paracetamol or simvastatin.

**Table 2. The Multivariate Predictors of Excessive Warfarin Anticoagulation.**

| Predictor                          | Multivariate Analysis OR (95% CI) | P-value |
|-----------------------------------|----------------------------------|---------|
| **Temporary**                     |                                  |         |
| Chemotherapeutic agents           | 5.61 (1.31–24.1)                 | 0.020   |
| Antibiotic or antifungal therapy⁴  | 4.57 (2.56–8.16)                 | <0.0001 |
| Recent medical treatment⁵         | 2.42 (1.56–3.75)                 | <0.0001 |
| **Lifestyle and independence**    |                                  |         |
| Alcohol abuse⁶                    | 24.4(9.85–50.4)                  | <0.0001 |
| Active smoking                    | 3.23 (1.19–8.77)                 | 0.021   |
| Not independent⁷                  | 2.63 (1.73–4.00)                 | <0.0001 |
| **Permanent**                     |                                  |         |
| Severe renal dysfunction⁸         | 15.2 (5.70–40.7)                 | <0.0001 |
| Mechanical heart valve            | 15.0 (1.74–129)                  | 0.014   |
| Active malignancy                | 7.07 (3.46–14.4)                 | <0.0001 |
| Chronic heart failure             | 2.78 (1.80–4.31)                 | <0.0001 |
| Treatment for hypertension        | 0.62 (0.43–0.92)                 | 0.016   |
| Cholesterol-lowering drugs        | 0.45 (0.30–0.67)                 | 0.001   |

Cl = confidence interval; OR = odds ratio

⁴Antibiotic or antifungal medication in the preceding 14 days.
⁵Hospitalization or outpatient visit in the preceding 1 month
⁶Alcohol related diagnosis or a hospital/health care center visit due to alcohol use
⁷Patient requiring outside help in daily routines
⁸eGFR < 30 ml/min/1.73 m², data missing on 27 patients (3.3%)

https://doi.org/10.1371/journal.pone.0175975.t002

Lifestyle and independence related factors

A total of 239 (58.0%) patients with EWA and 76 (18.8%) control patients had risk factors associated with lifestyle or were dependent on help from other people in everyday life. The lifestyle related significant predictors were active smoking, and excessive alcohol consumption. Alcohol abuse was observed in 17.7% of patients in the EWA Group and only 1.5% of control patients, predicting EWA with an odds ratio of over 20.

**Discussion**

Non-vitamin K antagonist oral anticoagulants (NOACs) are increasingly used as the first choice for anticoagulation in patients with AF, but warfarin is still widely used and remains the only option for patients with mechanical valve prosthesis [12–14]. Our study shows that severe overanticoagulation is a rare phenomenon during warfarin treatment and can be predicted with many patient characteristics together with temporary predisposing factors highlighting the complexity and multifactorial etiology of excessive anticoagulation. By identifying these risk factors, it is possible to improve the safety of warfarin anticoagulation.
Our results show that even though long-term warfarin treatment exposes to overanticoagulation over time, the first months after introduction of the treatment carry the highest risk (Fig 1). This finding is in line with earlier reports on risks of major bleeding and overanticoagulation during warfarin treatment [2, 15–17]. AF is detected and anticoagulation often initiated in an acute setting such as exacerbation of chronic disease or acute decompensated heart failure. Therefore, early dosing may be affected by concomitant medications, or patients may not be accustomed to nutrients affecting vitamin K metabolism.

Excessive alcohol consumption was associated with the greatest (24-fold) individual risk of EWA, reflecting the many problems of alcohol abuse with warfarin treatment: direct alcohol inhibition of warfarin breakdown, impairment of liver function and problems in drug compliance [18]. Active smokers were also found to be at risk of overanticoagulation and as with alcohol abuse, addiction treatment may prove useful also in stabilizing INR levels. Given the obvious reasons for EWA in patients with alcohol abuse, a critical assessment of patient’s net clinical benefit of anticoagulation therapy should be undertaken. Theoretically, some of these patients could benefit from NOACs instead of warfarin use, but this concept has not been proven in clinical trials nor in real world practice.

It is well known that in patients with heart failure, malignancies and chronic kidney diseases an episode of very high INR may reflect the overall disease burden and exacerbations of...
the underlying disease. Spontaneous INR elevations are often present at the end stage of a critical illness and the high INR is a consequence of the disease process rather than a specific problem with warfarin. Reflecting this background, chronic heart failure was very common among EWA patients. Even though heart failure is an established risk factor for ischemic stroke in AF patients, congestion may impair liver function and reduce the synthesis of coagulation factors thus predisposing also to excessive anticoagulation [19]. In addition to heart failure, advanced age and active cancer have been reported to prolong the return of elevated INR to therapeutic level [20].

Chronic kidney disease is a common finding among AF patients and a major risk factor for a bleeding event, cardiovascular and all-cause mortality also in patients with only mild renal impairment [21–25]. Expectedly, severe renal dysfunction was also a strong predictor of EWA. This result highlights the need for careful assessment of indications and bleeding risks when considering anticoagulation for patients with AF and severe renal impairment. For patients with AF on hemodialysis, the bleeding risks are often thought to outweigh the benefits of oral anticoagulation [26, 27]. This reasoning is supported by our current findings, as all our study patients with kidney failure (eGFR <15) suffered an EWA event.

Malignant diseases are known to be prothrombotic, but in patients on warfarin, active cancer also seems to increase the risk of overanticoagulation. Nevertheless, only a minority of patients in this study had an active malignancy. This can be partly explained by the use of low molecular weight heparin in cancer patients, although there is no clear recommendation on its use among AF patients in contrast to patients with deep vein thrombosis [28]. In patients with mechanical valve prosthesis the risk of EWA was high (15-fold) and may be a result of a higher target INR level than in patients with AF. One possible explanation may be excessive dose elevation due to fear of thromboembolic complications in subtherapeutic INR levels, although the actual target INR is only slightly higher than that for AF patients. In fact, this finding is in line with the recent publication by Grzymala-Lubanski et al reporting a higher incidence of bleedings, death and total complications related to higher warfarin intensity in comparison to lower intensity of anticoagulation [14, 29].
In accordance with previous studies, antibiotic or antifungal treatments were strong predictors of EWA and all study patients with antifungal medication experienced EWA [30, 31]. More frequent INR controls together with critical prescription policy might help to avoid these events or at least to detect them earlier. Concomitant use of known interactive medication should be avoided to reduce the risk of INR instability and bleeding events [32, 33]. The low rates of interactive medication in our study may be explained by the national electronic database for interactive medication (Swedish, Finnish, Interaction X-referencing database) used widely in clinical practice in Finland. Interestingly, cholesterol-lowering drugs were found to make an EWA event 50% less likely. This is in accordance with a previous smaller report on statin therapy protecting warfarin treated patients against overanticoagulation [17].

Outpatient emergency visits and hospitalizations were also independent risk factors for severe overanticoagulation. While the above mentioned chronic underlying diseases/conditions may affect the level of warfarin anticoagulation, it is also possible that physicians tend to adjust warfarin dosage based on incidental INR values at the hospital without appropriate knowledge on long-term dosing or drug adherence. Furthermore, these treatment episodes may also include procedures during which warfarin discontinuations may be necessary and the following reinitiation of warfarin potentially exposes to overanticoagulation. These findings highlight the need of frequent outpatient INR controls in these acute settings together with better patient education.

It was not a surprise that patients who are institutionalized or otherwise dependent on outsider help in everyday life were also at risk of EWA. This may be a reflection of worse overall health status or non-adherence to medication [34]. Even though the simple dosage of NOACs might prove more practical in this subgroup, the detection of overanticoagulation might be more difficult compared to warfarin treatment with regular INR controls.

The Turku University Hospital laboratory service provider (TYKSLAB) has exceptionally comprehensive follow-up data coverage with virtually all INR samples analyzed by the same laboratory regardless of the place of residence in the southwestern Finland. Also, people living in this region have no tendency for migration enabling reliable and comprehensive follow-up data. This unusual setting provides invaluable data for our analysis. Even though the electronic patient records have good coverage, we were reliant on the clinical data and diagnoses documented by the physicians and other medical professionals taking care of the patient. Information on the level of adherence to medication or warfarin dosage on patient records was scarce and thus not registered. To ensure the stability of INR in the control group patients, we used a method, which favors the selection of patients with longer treatment durations. For this reason, the comparison of treatment duration between groups was not presented. The selection of patients with the least INR elevations on long-term warfarin anticoagulation (Control group) will by definition favor patients with low-risk for complications.”

Conclusions

Our large retrospective study shows that the rare and complex complication of severe warfarin anticoagulation can be predicted with several clinical factors. Identifying the risk factors may be helpful in prevention and early detection of episodes of very high INR.

Acknowledgments

We thank our study coordinator Tuija Vasankari, RN, for her input in study management and Ari Törnä, MSc for providing laboratory data for the study, and Henri Sallinen, BM, Marianne Mäkäräinen, BM and Aku Virta, BM, for the help in the collection of the data.
Author Contributions
Conceptualization: KEJA SJ IN TOK.
Data curation: SJ IN MI.
Formal analysis: SJ IN TOK KEJA.
Funding acquisition: KEJA.
Investigation: MI SJ RV.
Methodology: KEJA IN TOK SJ.
Project administration: KEJA.
Resources: KEJA.
Software: IN.
Supervision: KEJA TOK.
Validation: IN SJ TOK KEJA.
Visualization: SJ.
Writing – original draft: SJ.
Writing – review & editing: SJ KEJA TOK MI RV IN.

References
1. Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003; 349(11):1019–26. Epub 2003/09/12. https://doi.org/10.1056/NEJMoa022913 PMID: 12968085
2. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation. 2007; 115(21):2689–96. Epub 2007/03/23. https://doi.org/10.1161/CIRCULATIONAHA.106.653048 PMID: 17514645
3. van Walraven C, Oake N, Wells PS, Forster AJ. Burden of potentially avoidable anticoagulant-associated hemorrhagic and thromboembolic events in the elderly. Chest. 2007; 131(5):1508–15. Epub 2007/02/24. https://doi.org/10.1378/chest.06-2628 PMID: 17317732
4. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D’Angelo A, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet. 1996; 348(9025):423–8. Epub 1996/08/17. PMID: 8709780
5. Koo S, Kucher N, Nguyen PL, Fanikos J, Marks PW, Goldhaber SZ. The effect of excessive anticoagulation on mortality and morbidity in hospitalized patients with anticoagulant-related major hemorrhage. Arch Intern Med. 2004; 164(14):1557–60. Epub 2004/07/28. https://doi.org/10.1001/archinte.164.14.1557 PMID: 15277289
6. Dodson JA, Petrone A, Gagnon DR, Tinetti ME, Krumholz HM, Gaziano JM. Incidence and Determinants of Traumatic Intracranial Bleeding Among Older Veterans Receiving Warfarin for Atrial Fibrillation. JAMA Cardiol. 2016; 1(1):65–72. Epub 2016/07/22. https://doi.org/10.1001/jamacardio.2015.0345 PMID: 27437657
7. Oden A, Fahlen M. Oral anticoagulation and risk of death: a medical record linkage study. Brmj. 2002; 325(7372):1073–5. Epub 2002/11/09. PubMed Central PMCID: PMCPMC131183. PMID: 12424167
8. Airaksinen KE, Gronberg T, Nuotio I, Nikkinen M, Ylitalo A, Biancali F, et al. Thromboembolic complications after cardioversion of acute atrial fibrillation: the FinCV (Finnish Cardioversion) study. J Am Coll Cardiol. 2013; 62(13):1187–92. Epub 2013/07/16. https://doi.org/10.1016/j.jacc.2013.04.089 PMID: 23850908
9. Palomaki A, Mustonen P, Hartikainen JE, Nuotio I, Kiviniemi T, Ylitalo A, et al. Strokes after cardioversion of atrial fibrillation—The FibStroke study. Int J Cardiol. 2016; 203:269–73. Epub 2015/11/01. https://doi.org/10.1016/j.ijcard.2015.10.168 PMID: 26519683

10. Chapter 1: Definition and classification of CKD. Kidney Int Suppl (2011). 2013; 3(1):19–62. Epub 2013/01/01. PubMed Central PMCID: PMCPMC4089693.

11. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Brmj. 2007; 335(7624):806–8. Epub 2007/10/20. PubMed Central PMCID: PMCPMC2034723. https://doi.org/10.1136/bmj.39335.541782.AD PMID: 17947786

12. Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013; 369(13):1206–14. Epub 2013/09/03. https://doi.org/10.1056/NEJMoa1300615 PMID: 23991661

13. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Guyton RA, et al. AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014; 63(22):e57–185. Epub 2014/03/08. https://doi.org/10.1016/j.jacc.2014.02.536 PMID: 24603191

14. Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Baron-Esquivias G, Baumgartner H, et al. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J. 2012; 33(19):2451–96. Epub 2012/08/28. https://doi.org/10.1036/eurheartj/ehs109 PMID: 22922415

15. Bergman M, Dicker D, Blumberger N, Brener ZZ, Ori Y, Salman H. Prolonged international normalized ratio during the first year of warfarin treatment. Am J Med Sci. 2014; 348(1):71–4. Epub 2014/06/21. https://doi.org/10.1097/MAJ.0000000000000209 PMID: 24949726

16. Fihn SD, McDonell M, Martin D, Henikoff J, Vermes D, Kent D, et al. Risk factors for complications of chronic anticoagulation. A multicenter study, Warfarin Optimized Outpatient Follow-up Study Group. Ann Intern Med. 1993; 118(7):511–20. Epub 1993/04/01. PMID: 8280198

17. Marie I, Leprince P, Menard JF, Tharasse C, Levesque H. Risk factors of vitamin K antagonist overcoagulation. Qjm. 2012; 105(1):53–62. Epub 2011/09/02. https://doi.org/10.1093/qjmed/hcr136 PMID: 21880698

18. Reddy U, Mallepadi NR, Chevassut TJ. High INR on warfarin. Brmj. 2015; 350:h1282. Epub 2015/04/11. https://doi.org/10.1136/bmj.h1282 PMID: 25858914

19. Visser LE, Bleumink GS, Trienekens PH, Vulto AG, Hofman A, Stricker BH. The risk of overanticoagulation in patients with heart failure on coumarin anticoagulants. Br J Haematol. 2004; 127(1):85–9. Epub 2004/09/24. https://doi.org/10.1111/j.1365-2141.2004.05162.x PMID: 15384981

20. Hylek EM, Regan S, Go AS, Hughes RA, Singer DE, Skates SJ. Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin. Ann Intern Med. 2001; 135(6):393–400. Epub 2001/09/19. PMID: 11560452

21. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003; 108(17):2154–69. Epub 2003/10/29. https://doi.org/10.1161/01.CIR.0000095676.90936.80 PMID: 14581387

22. Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol. 2006; 17(7):2034–47. Epub 2006/06/02. https://doi.org/10.1681/ASN.2005101085 PMID: 16738019

23. Lutz J, Menke J, Sollinger D, Schinzel H, Thurmell K. Haemostasis in chronic kidney disease. Nephrol Dial Transplant. 2014; 29(1):29–40. Epub 2013/10/18. https://doi.org/10.1093/ndt/gft209 PMID: 24132242

24. Pavord S, Myers B. Bleeding and thrombotic complications of kidney disease. Blood Rev. 2011; 25(6):271–8. Epub 2011/08/30. https://doi.org/10.1016/j.bler.2011.07.001 PMID: 21872374

25. Boriani G, Laroche C, Diemerberger I, Popescu MI, Rasmussen LH, Petrescu L, et al. Glomerular filtration rate in patients with atrial fibrillation and 1-year outcomes. Sci Rep. 2016; 6:30271. Epub 2016/07/29. PubMed Central PMCID: PMCPMC4964613. https://doi.org/10.1038/srep30271 PMID: 27466080

26. Wizemann V, Tong L, Satayathum S, Disney A, Akiba T, Fissell RB, et al. Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int. 2010; 77(12):1098–106. Epub 2010/01/08. https://doi.org/10.1038/ki.2009.477 PMID: 20554291

27. Garg L, Chen C, Haines DE. Atrial fibrillation and chronic kidney disease requiring hemodialysis—Does warfarin therapy improve the risks of this lethal combination? Int J Cardiol. 2016; 222:47–50. Epub 2016/07/30. https://doi.org/10.1016/j.ijcard.2016.07.118 PMID: 27472258
28. Buller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 126(3 Suppl):401s–28s. Epub 2004/09/24. https://doi.org/10.1378/chest.126.3_suppl.401S PMID: 15383479

29. Grzymala-Lubanski B, Svensson PJ, Renlund H, Jeppsson A, Sjalander A. Warfarin treatment quality and prognosis in patients with mechanical heart valve prosthesis. Heart. 2017; 103(3):198–203. Epub 2016/09/04. https://doi.org/10.1136/heartjnl-2016-309585 PMID: 27590664

30. Wittkowsky AK, Devine EB. Frequency and causes of overanticoagulation and underanticoagulation in patients treated with warfarin. Pharmacotherapy. 2004; 24(10):1311–6. Epub 2005/01/05. PMID: 15628828

31. Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005; 165(10):1095–106. Epub 2005/05/25. https://doi.org/10.1001/archinte.165.10.1095 PMID: 15911722

32. Pottegard A, Meegaard PM, Holck LH, Christensen R, Madsen H, Hallas J. Concurrent use of tramadol and oral vitamin K antagonists and the risk of excessive anticoagulation: a register-based nested case-control study. Eur J Clin Pharmacol. 2013; 69(3):641–6. Epub 2012/08/01. https://doi.org/10.1007/s00228-012-1363-x PMID: 22847619

33. Gasse C, Hollowell J, Meier CR, Haefeli WE. Drug interactions and risk of acute bleeding leading to hospitalisation or death in patients with chronic atrial fibrillation treated with warfarin. Thromb Haemost. 2005; 94(3):537–43. Epub 2005/11/05. https://doi.org/10.1160/TH05-03-0166 PMID: 16268469

34. Luzny J, Ivanova K, Jurickova L. Non-adherence in seniors with dementia—a serious problem of routine clinical practice. Acta Medica (Hradec Kralove). 2014; 57(2):73–7. Epub 2014/09/27.